Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
- Status
- COMPLETED
- Phase
- PHASE2
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
- Status
- COMPLETED
- Phase
- PHASE1
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- Status
- COMPLETED
- Phase
- PHASE2
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
- Status
- RECRUITING
- Phase
- PHASE2
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Status
- COMPLETED
- Phase
- PHASE2
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3